MedTrace Logo

Implementing Long-Acting Novel Antiretrovirals

NCT05294159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2024-07-08

No results posted yet for this study

Summary

This is a 12-month, dual arm, phase 4, open-label, multi-centre study examining the implementation of LA intra-muscular (IM) drugs in clinics and decentralised community-based settings in the UK.

Conditions

  • Human Immunodeficiency Viruses

Interventions

OTHER

The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)

The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability

Sponsors & Collaborators

  • Chelsea and Westminster NHS Foundation Trust

    collaborator OTHER

  • Barts & The London NHS Trust

    collaborator OTHER

  • Guy's and St Thomas' NHS Foundation Trust

    collaborator OTHER

  • Royal Free Hospital NHS Foundation Trust

    collaborator OTHER

  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV

  • Brighton and Sussex University Hospitals NHS Trust

    collaborator OTHER

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Chloe Orkin · QMUL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2023-12-22
Completion
2023-12-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294159 on ClinicalTrials.gov